Molecular imaging in the management of gynecologic malignancies

Gynecologic Oncology

Volumn 135, Issue 1, 2014, Pages 156-162

  Lai, Chyong Huey ^a   Lin, Gigin ^a   Yen, Tzu Chen ^a   Liu, Feng Yuan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

FDG; Gynecologic malignancies molecular imaging; MRI; PET; PET CT; Spectroscopy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 16A FLUOROESTRADIOL 17B F 18; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; 3' FLUOROTHYMIDINE F 18; 4 FLUOROBENZOYL ANNEXIN 5 F 18; 6 FLUORODIHYDROXYPHENYLALANINE F 18; ACETIC ACID C 11; AMMONIA N 13; CARBON 11; CHOLINE C 11; COPPER 64; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; GALACTO ARGININE GLYCINE ASPARTATE F 18; METHIONINE C 11; OXYGEN 15; PALMITIC ACID C 11; RUBIDIUM 82; SODIUM FLUORIDE F 18; THYMIDINE C 11; TRACER; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; WATER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMICAL EXCHANGE SATURATION TRANSFER IMAGING; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DYNAMIC NUCLEAR POLARIZATION; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; GYNECOLOGIC SURGERY; HUMAN; INTERMETHOD COMPARISON; LEIOMYOSARCOMA; META ANALYSIS (TOPIC); MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; OVARY CANCER; PATIENT MONITORING; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; UTERINE CERVIX CANCER; UTERUS CANCER; UTERUS SARCOMA; VULVA CANCER; GENITAL NEOPLASMS, FEMALE; MULTIMODAL IMAGING; PROSPECTIVE STUDY;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907991461     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.07.092     Document Type: Review

References (77)

1. D.A. Mankoff, D.A. Pryma, and A.S. Clark Molecular imaging biomarkers for oncology clinical trials J Nucl Med 55 4 2014 525 528
2. L.K. Shankar The clinical evaluation of novel imaging methods for cancer management Nat Rev Clin Oncol 9 12 2012 738 744
3. D.M. Koh, and D.J. Collins Diffusion-weighted MRI in the body: applications and challenges in oncology Am J Roentgenol 188 6 2007 1622 1635
4. N. Hylton Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker J Clin Oncol 24 20 2006 3293 3298
5. K. Glunde, and Z.M. Bhujwalla Metabolic tumor imaging using magnetic resonance spectroscopy Semin Oncol 38 1 2011 26 41
6. C.H. Lai, T.C. Yen, and T.C. Chang Positron emission tomography imaging for gynecologic malignancy Curr Opin Obstet Gynecol 19 1 2007 37 41
7. 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis J Nucl Med 55 3 2014 414 422
8. D.A. Torigian, H. Zaidi, T.C. Kwee, B. Saboury, J.K. Udupa, and Z.H. Cho PET/MR imaging: technical aspects and potential clinical applications Radiology 267 1 2013 26 44
9. S. Risum, C. Hogdall, A. Loft, A.K. Berthelsen, E. Hogdall, and L. Nedergaard The diagnostic value of PET/CT for primary ovarian cancer - a prospective study Gynecol Oncol 105 1 2007 145 149
10. A. Esseridou, G. Di Leo, L.M. Sconfienza, V. Caldiera, F. Raspagliesi, and B. Grijuela In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy Invest Radiol 46 6 2011 377 382
11. Y.O. Tanaka, M. Nishida, H. Tsunoda, Y. Okamoto, and H. Yoshikawa Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings J Magn Reson Imaging 20 6 2004 998 1007
12. K. Sato, N. Yuasa, M. Fujita, and Y. Fukushima Clinical application of diffusion-weighted imaging for preoperative differentiation between uterine leiomyoma and leiomyosarcoma Am J Obstet Gynecol 210 4 2014 [368 e1-8]
13. 18F-FDG PET in differentiating malignant uterine corpus tumors from benign leiomyoma Ann Nucl Med 26 6 2012 478 484
14. C.H. Lai, T.C. Yen, and K.K. Ng Molecular imaging in the management of cervical cancer J Formos Med Assoc 111 8 2012 412 420
15. Y. Lakhman, O. Akin, K.J. Park, D.M. Sarasohn, J. Zheng, and D.A. Goldman Stage IB1 cervical cancer: role of preoperative MR imaging in selection of patients for fertility-sparing radical trachelectomy Radiology 269 1 2013 149 158
16. D.G. Mitchell, B. Snyder, F. Coakley, C. Reinhold, G. Thomas, and M. Amendola Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study J Clin Oncol 24 36 2006 5687 5694
17. H. Hricak, C. Gatsonis, D.S. Chi, M.A. Amendola, K. Brandt, and L.H. Schwartz Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183 J Clin Oncol 23 36 2005 9329 9337
18. E. Epstein, A. Testa, A. Gaurilcikas, A. Di Legge, L. Ameye, and V. Atstupenaite Early-stage cervical cancer: tumor delineation by magnetic resonance imaging and ultrasound - a European multicenter trial Gynecol Oncol 128 3 2013 449 453
19. D.G. Mitchell, B. Snyder, F. Coakley, C. Reinhold, G. Thomas, and M.A. Amendola Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study Gynecol Oncol 112 1 2009 95 103
20. G. Lin, K.C. Ho, J.J. Wang, K.K. Ng, Y.Y. Wai, and Y.T. Chen Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T J Magn Reson Imaging 28 1 2008 128 135
21. 18F]-fluoro-2-deoxy-d-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy J Clin Oncol 24 1 2006 123 128
22. K. Kitajima, E. Yamasaki, Y. Kaji, K. Murakami, and K. Sugimura Comparison of DWI and PET/CT in evaluation of lymph node metastasis in uterine cancer World J Radiol 4 5 2012 207 214
23. S.K. Kim, H.J. Choi, S.Y. Park, H.Y. Lee, S.S. Seo, and C.W. Yoo Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients Eur J Cancer 45 12 2009 2103 2109
24. C.H. Lai, and T.C. Yen When and how often should PET scans be performed in the management of cervical cancer? Expert Rev Anticancer Ther 10 7 2010 983 986
25. P.T. Ramirez, A. Jhingran, H.A. Macapinlac, E.D. Euscher, M.F. Munsell, and R.L. Coleman Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings Cancer 117 9 2011 1928 1934
26. E. Leblanc, H. Gauthier, D. Querleu, G. Ferron, S. Zerdoud, and P. Morice Accuracy of 18-fluoro-2-deoxy-d-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma Ann Surg Oncol 18 8 2011 2302 2309
27. H.H. Chou, H.P. Chang, C.H. Lai, K.K. Ng, S. Hsueh, and T.I. Wu (18)F-FDG PET in stage IB/IIB cervical adenocarcinoma/adenosquamous carcinoma Eur J Nucl Med Mol Imaging 37 4 2010 728 735
28. C.S. Tsai, C.H. Lai, T.C. Chang, T.C. Yen, K.K. Ng, and S. Hsueh A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy Int J Radiat Oncol 76 2 2010 477 484
29. A. Loft, A.K. Berthelsen, H. Roed, C. Ottosen, L. Lundvall, and J. Knudsen The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study Gynecol Oncol 106 1 2007 29 34
30. 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging Cancer 115 23 2009 5470 5480
31. 18F]-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical cancer Int J Gynecol Cancer 23 2 2013 337 342
32. S.L. Antonsen, L.N. Jensen, A. Loft, A.K. Berthelsen, J. Costa, and A. Tabor MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study Gynecol Oncol 128 2 2013 300 308
33. G. Lin, K.K. Ng, C.J. Chang, J.J. Wang, K.C. Ho, and T.C. Yen Myometrial invasion in endometrial cancer: diagnostic accuracy of diffusion-weighted 3.0-T MR imaging-initial experience Radiology 250 3 2009 784 792
34. N.S. Horowitz, F. Dehdashti, T.J. Herzog, J.S. Rader, M.A. Powell, and R.K. Gibb Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer Gynecol Oncol 95 3 2004 546 551
35. R. Suzuki, E. Miyagi, N. Takahashi, A. Sukegawa, A. Suzuki, and I. Koike Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer Int J Gynecol Cancer 17 4 2007 890 896
36. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma Eur J Nucl Med Mol Imaging 35 3 2008 484 492
37. J. Hynninen, A. Auranen, O. Carpen, K. Dean, M. Seppanen, and J. Kemppainen FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread Gynecol Oncol 126 1 2012 64 68
38. Y. Yuan, Z.X. Gu, X.F. Tao, and S.Y. Liu Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis Eur J Radiol 81 5 2012 1002 1006
39. K. Michielsen, I. Vergote, K. Op de Beeck, F. Amant, K. Leunen, and P. Moerman Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT Eur Radiol 24 4 2014 889 901
40. M.Y. Kataoka, E. Sala, P. Baldwin, C. Reinhold, A. Farhadi, and T. Hudolin The accuracy of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-centre study Gynecol Oncol 117 1 2010 82 87
41. D.E. Cohn, F. Dehdashti, R.K. Gibb, D.G. Mutch, J.S. Rader, and B.A. Siegel Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer Gynecol Oncol 85 1 2002 179 184
42. E.A. Kidd, and P.W. Grigsby Intratumoral metabolic heterogeneity of cervical cancer Clin Cancer Res 14 16 2008 5236 5241
43. 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer Gynecol Oncol 127 1 2012 131 135
44. T.C. Yen, L.C. See, C.H. Lai, C.S. Tsai, A. Chao, and S. Hsueh Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer Eur J Nucl Med Mol Imaging 35 3 2008 493 501
45. K.C. Ho, C.C. Wang, J.T. Qiu, C.H. Lai, J.H. Hong, and Y.T. Huang Identification of prognostic factors in patients with cervical cancer and supraclavicular lymph node recurrence Gynecol Oncol 123 2 2011 253 256
46. 18FDG PET/CT as a predictor of high-risk endometrial cancer patients Gynecol Oncol 129 2 2013 298 303
47. K. Nakamura, I. Joja, C. Fukushima, T. Haruma, C. Hayashi, and T. Kusumoto The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer Eur J Nucl Med Mol Imaging 40 1 2013 52 60
48. 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma Gynecol Oncol 125 3 2012 566 571
49. NCCN Clinical Practice Guidelines in Oncology: Uterine Cancers National Comprehensive Cancer Network Web site http://www.nccn.org/professionals/physician-gls/pdf/uterine.pdf [Accessed July 03, 2014]
50. N.M. deSouza, W.P. Soutter, G. Rustin, M.M. Mahon, B. Jones, and R. Dina Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3-year outcome Br J Cancer 90 12 2004 2326 2331
51. V.N. Harry, S.I. Semple, F.J. Gilbert, and D.E. Parkin Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer Gynecol Oncol 111 2 2008 213 220
52. T.C. Chang, K.S. Law, J.H. Hong, C.H. Lai, K.K. Ng, and S. Hsueh Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study Cancer 101 1 2004 164 171
53. 18F]FDG PET/CT in patients with uterine cervical cancer Eur J Radiol 81 8 2012 e817 e822
54. 18F-FDG PET for recurrent cervical cancer J Nucl Med 45 10 2004 1632 1639
55. 18F]fluoro-2-deoxy-d-glucose positron emission tomography Cancer 100 3 2004 544 552
56. 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer Eur J Nucl Med Mol Imaging 33 12 2006 1399 1407
57. 18F]fluoro-2-deoxy-d-glucose positron emission tomography in re-recurrent cervical cancer Int J Gynecol Cancer 16 6 2006 1994 2003
58. J.Y. Park, E.N. Kim, D.Y. Kim, J.H. Kim, Y.M. Kim, and Y.T. Kim Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients Int J Gynecol Cancer 18 6 2008 1332 1338
59. 18F-FDG PET in the management of endometrial cancer Eur J Nucl Med Mol Imaging 33 1 2006 36 44
60. S. Sironi, M. Picchio, C. Landoni, S. Galimberti, M. Signorelli, and V. Bettinardi Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence Eur J Nucl Med Mol Imaging 34 4 2007 472 479
61. P. Sharma, R. Kumar, H. Singh, S. Jeph, J.B. Sharma, and S.K. Jain Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging Nucl Med Commun 33 2 2012 185 190
62. Y.H. Kao, U. Saad, A.E. Tan, B.M. Magsombol, and A.K. Padhy Fluorine-18-fluorodeoxyglucose PET/CT for the evaluation of suspected recurrent uterine leiomyosarcomas Acta Radiol 52 4 2011 463 466
63. M. Murakami, H. Tsukada, M. Shida, M. Watanabe, H. Maeda, and S. Koido Whole-body positron emission tomography with F-18 fluorodeoxyglucose for the detection of recurrence in uterine sarcomas Int J Gynecol Cancer 16 2 2006 854 860
64. 18F) fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery Int J Gynecol Cancer 19 4 2009 600 604
65. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer Int J Clin Oncol 10 3 2005 177 181
66. 18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings Eur J Nucl Med Mol Imaging 34 4 2007 480 486
67. J. Grueneisen, K. Beiderwellen, P. Heusch, P. Buderath, B. Aktas, and M. Gratz Correlation of standardized uptake value and apparent diffusion coefficient in integrated whole-body PET/MRI of primary and recurrent cervical cancer PLoS One 9 5 2014 e96751
68. S. Zhang, J. Xin, Q. Guo, J. Ma, Q. Ma, and H. Sun Comparison of tumor volume between PET and MRI in cervical cancer with hybrid PET/MR Int J Gynecol Cancer 24 4 2014 744 750
69. H. Sun, J. Xin, S. Zhang, Q. Guo, Y. Lu, and W. Zhai Anatomical and functional volume concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical cancer: a hybrid PET/MR study Eur J Nucl Med Mol Imaging 41 5 2014 898 905
70. 18F-FDG PET/CT imaging by texture analysis Eur J Nucl Med Mol Imaging 40 1 2013 133 140
71. F. Yang, M.A. Thomas, F. Dehdashti, and P.W. Grigsby Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer Eur J Nucl Med Mol Imaging 40 5 2013 716 727
72. F.J. Brooks On some misconceptions about tumor heterogeneity quantification Eur J Nucl Med Mol Imaging 40 8 2013 1292 1294
73. 2]fumarate is a marker of cell necrosis and treatment response in tumors Proc Natl Acad Sci U S A 106 47 2009 19801 19806
74. 13C]pyruvate Sci Transl Med 5 198 2013 98ra08
75. P.C. van Zijl, and N.N. Yadav Chemical exchange saturation transfer (CEST): what is in a name and what isn't? Magn Reson Med 65 4 2011 927 948
76. S. Walker-Samuel, R. Ramasawmy, F. Torrealdea, M. Rega, V. Rajkumar, and S.P. Johnson In vivo imaging of glucose uptake and metabolism in tumors Nat Med 19 8 2013 1067 1072
77. Z. Wen, S. Hu, F. Huang, X. Wang, L. Guo, and X. Quan MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrast Neuroimage 51 2 2010 616 622